| Catalog Number |
PR50847115 |
| CAS |
50847-11-5 |
| Description |
Ibudilast is an anti-inflammatory and neuroprotective oral agent. |
| Synonyms |
Ketas; KC-404; MN-166; Ibudilastum |
| IUPAC Name |
2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one |
| Molecular Weight |
230.31 |
| Molecular Formula |
C14H18N2O |
| InChI |
ZJVFLBOZORBYFE-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3 |
| Drug Categories |
Anti-Asthmatic Agents; Antiplatelet agents; Autonomic Agents; Bronchodilator Agents; Cardiovascular Agents; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Hematologic Agents; Heterocyclic Compounds, Fused-Ring; Leukotriene Antagonists; Peripheral Nervous System Agents; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Respiratory System Agents; Vasodilating Agents |
| Drug Interactions |
Abaloparatide-The risk or severity of hypotension can be increased when Ibudilast is combined with Abaloparatide.
Abciximab-The risk or severity of bleeding can be increased when Ibudilast is combined with Abciximab.
Abrocitinib-The risk or severity of bleeding and thrombocytopenia can be increased when Ibudilast is combined with Abrocitinib.
Acebutolol-Ibudilast may increase the antihypertensive activities of Acebutolol.
Aceclofenac-The risk or severity of bleeding can be increased when Aceclofenac is combined with Ibudilast. |
| Half-Life |
19 hours |
| Isomeric SMILES |
CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C |
| Standard |
In-house |
| Type |
Small Molecule |
| Therapeutic Category |
Ophthalmic Agents |
It should be noted that our service is only used for research, not for clinical use.
